Profile data is unavailable for this security.
About the company
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
- Revenue in USD (TTM)4.15m
- Net income in USD-131.56m
- Incorporated2011
- Employees68.00
- LocationSyros Pharmaceuticals Inc35 Cambridge Park DriveCAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 744-1340
- Fax+1 (617) 744-1377
- Websitehttps://syros.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allakos Inc | 0.00 | -206.00m | 48.16m | 131.00 | -- | 0.5733 | -- | -- | -2.35 | -2.35 | 0.00 | 0.9454 | 0.00 | -- | -- | 0.00 | -86.62 | -42.71 | -99.21 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
Reneo Pharmaceuticals Inc | 0.00 | -56.54m | 50.14m | 8.00 | -- | 0.6522 | -- | -- | -1.68 | -1.68 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -49.87 | -- | -53.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
Syros Pharmaceuticals Inc | 4.15m | -131.56m | 52.28m | 68.00 | -- | -- | -- | 12.60 | -4.30 | -4.30 | 0.1222 | -0.2369 | 0.0288 | -- | -- | 61,000.00 | -91.46 | -54.44 | -112.06 | -64.32 | -- | -- | -3,171.70 | -772.82 | -- | -- | 1.18 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Prenetics Global Ltd | 22.25m | -49.97m | 53.27m | 320.00 | -- | 0.2325 | -- | 2.39 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
Intensity Therapeutics Inc | 0.00 | -15.08m | 53.43m | 5.00 | -- | 9.95 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
Calcimedica Inc | 0.00 | -12.59m | 53.64m | 14.00 | -- | 3.88 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
Angion Biomedica Corp | 0.00 | -38.66m | 54.63m | 32.00 | -- | -- | -- | -- | -4.83 | -4.83 | 0.00 | -0.161 | 0.00 | -- | -- | 0.00 | -144.89 | -105.91 | -202.49 | -331.69 | -- | -- | -- | -712.81 | -- | -- | -- | -- | -100.00 | -- | 9.31 | -- | -- | -- |
Aerovate Therapeutics Inc | 0.00 | -87.94m | 54.85m | 51.00 | -- | 0.5808 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Actinium Pharmaceuticals Inc | 81.00k | -42.62m | 56.08m | 49.00 | -- | 1.25 | -- | 692.32 | -1.52 | -1.52 | 0.0029 | 1.43 | 0.0009 | -- | -- | 1,653.06 | -45.12 | -46.98 | -50.13 | -52.71 | -- | -- | -52,620.99 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Hookipa Pharma Inc | 52.16m | -48.60m | 57.14m | 151.00 | -- | 0.6639 | -- | 1.10 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
Mural Oncology PLC | 0.00 | -173.30m | 57.59m | 117.00 | -- | 0.2797 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Invus Public Equities Advisors LLCas of 25 Jul 2024 | 3.57m | 13.35% |
Adage Capital Management LPas of 30 Jun 2024 | 2.07m | 7.75% |
Avidity Partners Management LPas of 30 Jun 2024 | 1.67m | 6.26% |
Point72 Asset Management LPas of 30 Jun 2024 | 1.47m | 5.51% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 964.24k | 3.61% |
Opaleye Management, Inc.as of 30 Jun 2024 | 865.44k | 3.24% |
Deep Track Capital LPas of 30 Jun 2024 | 828.49k | 3.10% |
Kennedy Capital Management LLCas of 30 Jun 2024 | 427.54k | 1.60% |
Walleye Capital LLCas of 30 Jun 2024 | 285.80k | 1.07% |
UBS O'Connor LLCas of 30 Jun 2024 | 278.10k | 1.04% |